Top Back to top

MMVAR: A Randomised Controlled study of Velcade (Bortezomib) plus Thalidomide plus Dexamethasone compared to Thalidomide plus Dexamethasone for the treatment of myeloma patients progressing or relapsing after autologous transplantation

Chronic Malignancies Working Party (CMWP)
Study number:
2005-001628-35
Type of transplant:
 
Short title:
MMVAR
Study status:
Completed Patient Recruitment
Deadline for data collection:
 
Study design:
Randomised, parallel-group, open-label, multicentre study
Primary objective:
the hypothesis that treatment with Velcade plus Thalidomide plus Dexamethasone in combination, will result in a longer time progre‚Äčthe hypothesis that treatment with Velcade plus Thalidomide plus Dexamethasone in combination, will result in a longer time progression than Thalidomide plus Dexamethasone in subjects with relapsed or progressive myeloma after autologous transplanatation‚Äč.
Key inclusion criteria:
>=18 years old
Country:
France
Belgium
Germany
Switzerland
Austria
Italy
Czech Republic
Hungary
Israel
United Kingdom
Principal investigator:
Laurent Garderet
Principal investigator email:
 
EBMT Study coordinator:
Marleen van Os